• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺特异性膜抗原(PSMA)靶向治疗:从分子机制到去势抵抗性前列腺癌的临床突破

PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer.

作者信息

Wang Licheng, Lu Change, Wang Xin'an, Wu Denglong

机构信息

Department of Urology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Putuo District, Shanghai, 200065, China.

Department of Urology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Putuo District, Shanghai, 200065, China.

出版信息

Eur J Med Chem. 2025 Oct 15;296:117829. doi: 10.1016/j.ejmech.2025.117829. Epub 2025 May 30.

DOI:10.1016/j.ejmech.2025.117829
PMID:40466338
Abstract

Prostate cancer (PCa) is one of the most prevalent malignancies among men worldwide and remains the second leading cause of cancer-related mortality in this population. While androgen deprivation therapy (ADT) is initially effective, most patients eventually progress to castration-resistant prostate cancer (CRPC), a stage characterized by aggressive disease behavior and limited treatment options. Prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker in PCa pathogenesis, with its overexpression in malignant cells providing a compelling target for both diagnostic imaging and therapeutic intervention.This review explores the multifaceted role of PSMA in tumor progression, highlighting its involvement in neoangiogenesis, metabolic reprogramming, and therapeutic vulnerabilities. We critically examine the latest advancements in PSMA-targeted treatment strategies, including radioligand therapy (e.g., Lu-PSMA-617), antibody-drug conjugates, bispecific T-cell engagers, and small-molecule PSMA inhibitors. Clinical studies have demonstrated that PSMA-directed therapies can significantly reduce prostate-specific antigen (PSA) levels, improve radiographic progression-free survival (rPFS), and enhance patient-reported quality of life. However, challenges such as heterogeneous PSMA expression and acquired resistance necessitate further investigation. Ongoing clinical trials are actively exploring combinatory approaches, integrating PSMA-targeted therapy with radiotherapy, chemotherapy, and immunotherapy to optimize therapeutic efficacy. This review underscores the promise of PSMA-targeted strategies in advancing precision medicine for mCRPC, paving the way for improved survival outcomes and a better quality of life for affected patients.

摘要

前列腺癌(PCa)是全球男性中最常见的恶性肿瘤之一,并且仍然是该人群中癌症相关死亡率的第二大主要原因。虽然雄激素剥夺疗法(ADT)最初是有效的,但大多数患者最终会进展为去势抵抗性前列腺癌(CRPC),这一阶段的特征是疾病行为侵袭性强且治疗选择有限。前列腺特异性膜抗原(PSMA)已成为PCa发病机制中的关键生物标志物,其在恶性细胞中的过表达为诊断成像和治疗干预提供了极具吸引力的靶点。本综述探讨了PSMA在肿瘤进展中的多方面作用,强调了其在新生血管生成、代谢重编程和治疗易损性中的作用。我们批判性地审视了PSMA靶向治疗策略的最新进展,包括放射性配体疗法(如Lu-PSMA-617)、抗体药物偶联物、双特异性T细胞衔接器和小分子PSMA抑制剂。临床研究表明,PSMA导向疗法可显著降低前列腺特异性抗原(PSA)水平,改善影像学无进展生存期(rPFS),并提高患者报告的生活质量。然而,诸如PSMA表达异质性和获得性耐药等挑战需要进一步研究。正在进行的临床试验正在积极探索联合方法,将PSMA靶向治疗与放疗、化疗和免疫疗法相结合,以优化治疗效果。本综述强调了PSMA靶向策略在推进mCRPC精准医学方面的前景,为改善受影响患者的生存结果和提高生活质量铺平了道路。

相似文献

1
PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer.前列腺特异性膜抗原(PSMA)靶向治疗:从分子机制到去势抵抗性前列腺癌的临床突破
Eur J Med Chem. 2025 Oct 15;296:117829. doi: 10.1016/j.ejmech.2025.117829. Epub 2025 May 30.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.去势抵抗性前列腺癌中免疫组织化学和PET成像检测FAP和PSMA表达:一项转化性初步研究
J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037.
4
The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.靶向α治疗(Ac-225前列腺特异性膜抗原)在转移性去势抵抗性前列腺癌患者中的安全性和有效性:一项系统评价和荟萃分析
Prostate. 2025 May;85(6):541-557. doi: 10.1002/pros.24857. Epub 2025 Jan 26.
5
In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies.新型PSMA靶向放射性配体的体外和体内研究:通过两性离子化和白蛋白结合策略提高肿瘤摄取和治疗效果
Mol Pharm. 2025 Jul 7;22(7):3961-3975. doi: 10.1021/acs.molpharmaceut.5c00214. Epub 2025 Jun 10.
6
Tracing the global evolution of PSMA-targeted radioligand therapy in prostate cancer: clinical advancements, future directions, and challenges.追踪前列腺癌中靶向PSMA的放射性配体疗法的全球发展:临床进展、未来方向及挑战。
Q J Nucl Med Mol Imaging. 2025 Jun;69(2):86-98. doi: 10.23736/S1824-4785.25.03635-0. Epub 2025 May 7.
7
Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.三线治疗和 Lu-PSMA 放射性配体疗法治疗转移性去势抵抗性前列腺癌:系统评价。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.前列腺癌中对 RL-225Ac 的反应:先前接受 RL-177Lu 治疗的影响:文献系统评价。
Prostate. 2023 Jul;83(10):901-911. doi: 10.1002/pros.24531. Epub 2023 Apr 13.
10
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.奥拉帕利单药治疗或与阿比特龙联合用于治疗转移性去势抵抗性前列腺癌(mCRPC)且存在BRCA突变的患者。
Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.

引用本文的文献

1
Radionuclides Landscape in Prostate Cancer Theranostics.前列腺癌诊疗中的放射性核素概况
Int J Mol Sci. 2025 Jul 14;26(14):6751. doi: 10.3390/ijms26146751.